For instance, in lymphoma platelet-derived growth factor C (PDGF-C) secreted by CAFs can counteract the antiangiogenesis therapy by anti-VEGF antibodies, as PDGF-C substitutes VEGF in stimulating capillary outgrowth thus diminishing the treatment efficacy.78 This evidence concerns the gene VEGFA and lymphoma.